言語を選択

SLAMF7

SLAMF7 詳細

英語名	SLAM family member 7	市販薬剤の数	1
治験薬の数	8	ターゲットの別称	CS1，UNQ576/PRO1138，SLAMF7，Novel Ly9，SLAM Family Member 7，Membrane Protein FOAP-12，CD2 Subset 1，Protein 19A，CRACC，CD2-Like Receptor Activating Cytotoxic Cells，CD2-Like Receptor-Activating Cytotoxic Cells，19A24 Protein，CD319，19A，CD319 Antigen，Novel LY9 (Lymphocyte Antigen 9) Like Protein
研究＆開発段階	Approved

英語名	SLAM family member 7
ターゲットの別称	CS1，UNQ576/PRO1138，SLAMF7，Novel Ly9，SLAM Family Member 7，Membrane Protein FOAP-12，CD2 Subset 1，Protein 19A，CRACC，CD2-Like Receptor Activating Cytotoxic Cells，CD2-Like Receptor-Activating Cytotoxic Cells，19A24 Protein，CD319，19A，CD319 Antigen，Novel LY9 (Lymphocyte Antigen 9) Like Protein
市販薬剤の数	1
治験薬の数	8
研究＆開発段階	Approved

SLAMF7 製品リスト

属性
Protein (8)
製品ライブラリ
オンライン (8)
種
Human (6)Mouse (1)Rhesus macaque (1)
タグ
His Tag (5)Fc Tag (1)His Tag & Avi Tag (1)Mouse IgG Fc Tag (1)
マーカー
Unconjugated (4)Biotin-labeled (1)FITC Labeled (1)PE Labeled (2)

製品番号	種	発現システム	製品説明
HOT SL7-H5225	Human	HEK293	Human SLAMF7 / CRACC / CD319 Protein, His Tag, low Endotoxin (MALS verified)
HOT SL7-H82E0	Human	HEK293	Biotinylated Human SLAMF7 / CRACC / CD319 Protein, Avitag™,His Tag (MALS verified)
HOT SL7-HP2H3	Human	HEK293	PE-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag (Site-specific conjugation)
HOT SL7-HP2H6	Human	HEK293	PE-Labeled Human SLAMF7 / CRACC / CD319 Protein, His TagStar Staining
HOT SL7-R52H7	Rhesus macaque	HEK293	Rhesus macaque SLAMF7 / CRACC / CD319 Protein, His Tag (MALS verified)
SL7-H5256	Human	HEK293	Human SLAMF7 / CRACC / CD319 Protein, Fc Tag
SL7-HF2H7	Human	HEK293	FITC-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag
SL7-M5252	Mouse	HEK293	Mouse SLAMF7 / CRACC / CD319 Protein, Mouse IgG2a Fc Tag, low endotoxin

総数量8

SLAMF7バックグランド

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

SLAMF7分子の別称

SLAMF7,CD319,CS1,CRACC,19A,FOAP-12

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital)		Phase 2 Clinical	University Hospital Würzburg	Multiple Myeloma	詳細
dual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology)		Phase 1 Clinical	Wuhan Sian Biotechnology Co Ltd	Multiple Myeloma	詳細
BCMA-CS1 cCAR T-cell therapy		Phase 1 Clinical	iCell Gene Therapeutics LLC	Multiple Myeloma	詳細
SA102-CAR-T	SA-102; SA102	Phase 1 Clinical	Wuhan Sian Biotechnology Co Ltd	Multiple Myeloma	詳細
WS-CART-CS1	WS-CART-CS1	Phase 1 Clinical	Paula C. & Rodger O. Riney Blood Cancer Research, Washington University School Of Medicine	Multiple Myeloma	詳細
MB-104	MB-104; MB-105; MB-104 CS1 CAR; MB-105 PSCA CAR	Phase 1 Clinical	City Of Hope National Medical Center	Glioblastoma; Multiple Myeloma; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms	詳細
CS1 Targeted CAR T-cells (Yake Biotechnology)		Phase 1 Clinical	Shanghai YaKe Biotechnology Co Ltd	Multiple Myeloma	詳細
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology)		Clinical	Wuhan BioRaid Biotechnology Co Ltd	Hematologic Neoplasms	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Elotuzumab	PDL-063; HuLuc-63; BMS-901608	Approved	Abbvie Inc, Bristol-Myers Squibb Company	Empliciti	United States	Multiple Myeloma	Bristol-Myers Squibb Company	2015-11-30	Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Leukemia, Plasma Cell; Lymphoma; Multiple Myeloma; Polycythemia Vera; Primary Myelofibrosis; Smoldering Multiple Myeloma; Thrombocythemia, Essential	詳細